Guillaume Dorothée Inserm Research Fellow U938 SAINT ANTOINE RESEARCH CENTRE +33 (0)1 49 28 46 20 firstname.lastname@example.org
These results are published in the journal Brain.
A new immunotherapy strategy for treating Alzheimer’s disease. This may be validated by the new work carried out by the Inserm team “Immune System, Neuroinflammation and Neurodegenerative Diseases” at UMRS 938 “Saint-Antoine Research Centre” (Inserm/UPMC) in Paris. In recent years, a body of substantive work has enabled the start of gaining further insight into complex immune and neuroinflammatory mechanisms associated with Alzheimer’s disease. The Inserm team at the Saint-Antoine Research Centre offers further proof of concept on the efficacy of innovative immunotherapy strategy in mice that is based on an immunomodulation approach.
Researchers have shown, in earlier work with mice, that a specific population of T lymphocytes, known as T regulators (or Treg), modulated specific Ab peptide T lymphocytes that accumulate in the brains of sick people. “Treg cells may act in different ways to modulate T lymphocyte response in general. However, there are other aspects of neuroinflammatory reactions observed in this type of disease”, states Guillaume Dorothée, Inserm Research Fellow in charge of this study. As such, researchers chose to evaluate the effect of Treg cells on disease progression using a mouse model.
Interleukin-2: Therapeutic Strategy
To do this, they either depleted or amplified Treg cells at the early stage of the disease. They found that a Treg deficiency accelerated the onset of cognitive disorders and was associated with a decrease in the presence of microglial cells in deposits of Ab peptide.
By contrast, prolonged Treg amplification using low doses of interleukin-2 injected intraperitoneally increases the microglial cell response and delays the onset of memory impairment.
This immunomodulation approach involving the injection of low doses of interleukin-2, already tested in some bone marrow transplant clinical protocols and for type 1 diabetes, now seems to be a new therapeutic strategy for Alzheimer’s disease. Researchers are already planning a pilot clinical trial in humans and are also considering the possibility of modulating some specific sub-populations of T lymphocytes to refine the response.
Circulating tumor cells use the blood and lymphatic networks to disseminate within the body, forming metastases distant from the primary tumor. Inserm researcher Jacky Goetz and his Tumor Biomechanics team at the Molecular ImmunoRheumatology laboratory (Inserm/Université de Strasbourg) have helped to show ...
Regulatory T cells delay disease progression in Alzheimer-like Pathology Cira Dansokho1,2*, Dylla Ait Ahmed1,2*, Saba Aid2,3*, Cécile Toly-Ndour1,2*, Thomas Chaigneau1,2, Vanessa Calle1,2, Nicolas Cagnard4, Martin Holzenberger2,3, Eliane Piaggio5,6, Pierre Aucouturier1,2, Guillaume Dorothée1,2. 1 INSERM, UMRS 938, Saint-Antoine CdR, "Immune System, Neuroinflammation and Neurodegenerative Diseases" Laboratory,St-Antoine Hospital, F-75012, Paris, France. 2 Sorbonne Universities, UPMC Univ Paris 06, UMRS 938, Saint-Antoine CdR, Saint- Antoine Hospital, F-75012, Paris, France. 3 INSERM, UMRS 938, Saint-Antoine CdR, "Neuroendocrine mechanisms of longevity and age-related diseases" Laboratory, St-Antoine Hospital, F-75012, Paris, France. 4 Bioinformatics Platform, Faculty of Medicine Paris Descartes, Necker Hospital – Sick Children F-75012, Paris, France. 5 INSERM, U932, Curie Institute, Research Department; Center of Clinical Investigation (CICBT- 507), F-75005, Paris, France. 6 Sorbonne Universities, UPMC Univ Paris 06, CNRS, UMR7211, Immunology- Immunopathology-Immunotherapy, F-75013 Paris, France Brain, 01 February 2016 DOI: dx.doi.org/10.1093/brain/awv408